Jun. 11 at 6:29 PM
Piper Sandler reiterated
$EWTX Overweight-
$51-Best Idea and said, "
$EWTX remains one of our 2025 best ideas as we feel confident that sevasemten's BMD regulatory update in 2Q25 will indicate FDA giving the green light to file for accelerated approval."
$SRPT $CAPR
$BMY $CYTK
Piper Sandler added, "As investors may not yet appreciate sevasemten's opportunity in BMD, we believe clarity on next steps should drive share gains.
Subsequently, EDG-7500's 12- week Cohort D topline in 2H25 is another key catalyst de-risked for PoS with potential to establish no ECHO-based titrations (driving key differentiation vs CMIs).
Overall, we believe EDG-7500 has a unique value proposition in HCM (especially as nHCM remains an untapped population). All told, we remain bullish on
$EWTX stock and see meaningful upside opportunities into a catalyst-rich next ~18 months."
